The mechanisms underlying lenalidomide-resistance of del(5q) MDS stem cells remain to be elucidated and may include cell-intrinsic as well as microenvironmental causes. Abnormal hypolobated megakaryocytes constitute one of the hallmarks of del(5q) MDS. We hypothesized that these cells have potential implications for the regulation of haematopoietic stem cells (HSC) similarly to what has recently been described for megakaryocytes in the murine system. Therefore, we conducted a study to determine the response of abnormal hypolobated megakaryocytes to lenalidomide therapy. We studied lenalidomide-treated patients in the MDS-004 trial as well as a cohort seen at our institution. Morphological evaluation at time of complete cytogenetic remission (CCyR) demonstrated the persistence of hypolobated megakaryocytes in all evaluable patients (n = 9). Furthermore, we provide evidence that the abnormal hypolobated morphology is restricted to del(5q) megakaryocytes, both at diagnosis and during CCyR. Using fluorescence in situ hybridisation analysis on flow-sorted stem-and progenitor populations, we observed a similar degree of clonal involvement in megakaryocyte-erythroid-progenitors as in HSC. Taken together, our findings suggest that megakaryocyte morphology might aid in the evaluation of patients where discontinuation of lenalidomide is considered and offers interesting hypotheses for further investigation of lenalidomide resistance.
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The mechanisms underlying lenalidomide-resistance of del(5q) MDS stem cells remain to be elucidated and may include cell-intrinsic as well as microenvironmental causes. Abnormal hypolobated megakaryocytes constitute one of the hallmarks of del(5q) MDS. We hypothesized that these cells have potential implications for the regulation of haematopoietic stem cells (HSC) similarly to what has recently been described for megakaryocytes in the murine system. Therefore, we conducted a study to determine the response of abnormal hypolobated megakaryocytes to lenalidomide therapy. We studied lenalidomide-treated patients in the MDS-004 trial as well as a cohort seen at our institution. Morphological evaluation at time of complete cytogenetic remission (CCyR) demonstrated the persistence of hypolobated megakaryocytes in all evaluable patients (n = 9). Furthermore, we provide evidence that the abnormal hypolobated morphology is restricted to del(5q) megakaryocytes, both at diagnosis and during CCyR. Using fluorescence in situ hybridisation analysis on flow-sorted stem-and progenitor populations, we observed a similar degree of clonal involvement in megakaryocyte-erythroid-progenitors as in HSC. Taken together, our findings suggest that megakaryocyte morphology might aid in the evaluation of patients where discontinuation of lenalidomide is considered and offers interesting hypotheses for further investigation of lenalidomide resistance.
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In myelodysplasia associated with del(5q), disease is sustained by rare clonally involved stem cells bearing the del (5q) abnormality (Nilsson et al, 2000; Woll et al, 2014) . While lenalidomide can induce complete cytogenetic remission (CCyR) and eradicate most del(5q) cells in the immature myeloid progenitor compartment, the rare myelodysplastic syndrome (MDS) stem cells have been shown to persist following lenalidomide therapy. Although the mechanisms underlying lenalidomide-resistance of del (5q) MDS stem cells remain to be elucidated, these resistant cancer stem cells are the likely cause of relapse in the majority of patients (Tehranchi et al, 2010; Fenaux et al, 2011; Giagounidis et al, 2012; Saft et al, 2014; Woll et al, 2014) . In addition, resistant haematopoietic stem cells (HSC) carrying del(5q) may also allow for continued accrual of somatic mutations in this cellular compartment and we recently demonstrated that progression to higher-risk MDS or acute myeloid leukaemia is universally associated with accumulation of additional driver mutations Scharenberg et al, 2017) . However, a small proportion of del (5q) patients may remain in durable clinical remission despite of treatment discontinuation, but the features characterizing these patients have not been identified (Giagounidis et al, 2012) .
All cells in the bone marrow receive input from microenvironmental niches that regulate their maintenance, proliferation and differentiation. In the setting of haematological disease, microenvironmental changes in bone marrow stroma can result either from pressure exerted by the neoplastic clone in remodelling a supportive microenvironment or from chronic perturbation of homeostasis in the bone marrow (Li & Neaves, 2006; Walkley et al, 2007; Vener et al, 2008; Raaijmakers, 2011; Schepers et al, 2015) .
Whether or not the niche in MDS is perturbed and exerting a dominant constraint towards healthy haematopoiesis remains a contentious issue (Deeg, 2002; Soenen-Cornu et al, 2005; Raaijmakers, 2012; Ferrer et al, 2013; Medyouf et al, 2014) . Some of the conflicting results are probably explained by the heterogeneity of MDS. Our recent analysis of the stromal microenvironment in a pure del(5q) cohort demonstrated only minor differences between pre-treatment del(5q) and healthy mesenchymal stromal cells (Scharenberg et al, 2017) . In the present study, we are the first to focus on megakaryocytes as a component of the non-mesenchymal environment in MDS. Given that abnormal hypolobated megakaryocytes constitute a hallmark of del(5q) MDS, we hypothesize that these cells could have potential implications for the response of HSC to treatment (Bruns et al, 2014; Zhao et al, 2014) . Therefore, we conducted a study to determine the response of abnormal hypolobated megakaryocytes to lenalidomide therapy.
Materials & methods

Patients and samples
The MDS-004 trial assessed the efficacy and safety of lenalidomide in 205 patients with International Prognostic Scoring System low-or intermediate-1-risk del(5q) MDS who were dependent on red blood cell transfusions . Information about inclusion criteria, treatment schedule, and clinical variables at study entry can be found in the original report . We previously described a detailed immunohistochemical analysis of bone marrow biopsies from 85 of these patients (Saft et al, 2014) . The current analysis was conducted under the ethical consent for the MDS-004 study Saft et al, 2014) . Eligible patients (n = 21) for the present analysis were those with available bone marrow biopsies for analysis of megakaryocyte morphology from at least two time-points.
In addition we obtained bone marrow samples from 35 consecutive low-risk and red blood cell transfusion-dependent del(5q) MDS patients at Karolinska University Hospital Huddinge between 2004 and 2016, 22 of whom were treated with lenalidomide (Scharenberg et al, 2017) . The detailed analyses of clinical parameters have been described previously (Scharenberg et al, 2017) . All patients provided written informed consent in accordance with the Institutional Review Board at Stockholm County.
Morphology and immunohistochemistry
Details are described in Saft et al (2014) . In brief, bone marrow cellularity and fibrosis were assessed according to European consensus guidelines (Thiele et al, 2005) .
Megakaryocyte dysplasia was defined by the presence of micromegakaryocytes, non-lobulated (hypolobated) megakaryocytes and megakaryocytes with widely separate nuclei. Dysmegakaryocytopoiesis was evaluated with two cut-off levels, 10% according to the World Health Organisation and 40% based on previous data (Germing et al, 2000; Matsuda et al, 2007) . Sequential bone marrow samples were assessed in a blinded fashion by routine morphology and immunohistochemistry. To label and identify megakaryocytes, immunofluorescence was performed using CD61 (clone Y2/ 51, Agilent, Santa Clara, CA, USA) according to the manufacturers' instructions.
Isolation of human megakaryocytes
Megakaryocytes were enriched from freshly aspirated human bone marrow samples from the Karolinska cohort by previously published methods using Percoll density gradient fractionation (Tomer et al, 1988) . Subsequently, cells were collected, washed and isolated using CD61-microbeads (Miltenyi Biotec Norden, Lund, Sweden) according to manufacturer's instructions.
Karyotyping and fluorescence in-situ hybridization (FISH)
Karyotyping was performed according to standard procedures. In the case of progenitor cell subset isolation by flow cytometric cell sorting, cell populations were spun onto glass slides, which were subsequently treated with pepsin and fixed with formaldehyde/MgCl 2 to detect deletions of 5q31, we used either the LSI EGR1/D5S721, D5S23 Dual Colour Probe (Abbott-Vysis, Downers Grove, IL, USA) or the ZytoLight SPEC EFR1/5p15 Dual Colour probe (ZytoVision, Bremerhaven, Germany). While deletions of 5q31 appear red using the EGR1-probe by Abbott-Vysis, the ZytoLight probe labels the same region green. Probes detecting 5p15Á2 or 5p15Á33 serve as an internal control and appear green in the kit by Abbott-Vysis and red in the ZytoVision kit. Probes were applied as recommended by the manufacturer. Disappearance of del(5q) was scored as complete cytogenetic response by evaluating at least 20 metaphases by standard karyotyping and/or 100 cells by FISH. Samples were considered negative for del(5q) if (i) none of 20 metaphases showed the karyotypic abnormality (standard karyotyping); (ii) levels were below the set detection threshold of FISH-analysis [8% for patients in MDS-004 or 5% for patients studied in the Karolinska cohort, according to the original publications (G€ ohring et al, 2011; Scharenberg et al, 2017) ].
Concomitant FISH on haematoxylin-eosin stained bone marrow sections
To study whether the hypolobated megakaryocyte morphology is associated with del(5q) aberration, bone marrow tissue sections were stained with haematoxylin-eosin for identification of hypolobated megakaryocytes. Subsequently, slides were scanned using 3DHistech scanner (Histolab, Askim, Sweden) and both normal and hypolobated megakaryocytes were enumerated. After being pre-treated with the Histology FISH accessory kit (DAKO/Agilent, Santa Clara, CA, USA) FISH was performed according to the method outlined above. Nuclei were identified using 4 0 ,6-diamidino-2-phenylindole (DAPI).
Flow cytometry
Haematopoietic stem cells, as well as three downstream subsets of myeloid progenitors, including common myeloid progenitors (CMP), granulocyte-macrophage progenitors (GMP), and megakaryocyte-erythroid progenitors (MEP) were isolated as described in our previous report and analysed for 7 patients from the Karolinska Cohort (Scharenberg et al, 2017) . Briefly, we isolated cell populations from CD34-enriched normal and MDS mononuclear cells by fluorescence-activated cell sorting (FACS) on a FACS Aria (BD Biosciences, San Jose, CA, USA). Our isolation-strategy was based on a panel of antibodies of the following surface markers:
Results
Hypolobated megakaryocytes pathognomonic for del(5q) MDS persist despite complete cytogenetic response to Lenalidomide
During morphological bone marrow examination of del(5q) patients treated with lenalidomide, we observed that hypolobated megakaryocytes persisted in all 22 patients despite complete clinical response to lenalidomide treatment. Knowing that del(5q) may persist in HSC at CCyR (Tehranchi et al, 2010) , we examined whether or not del(5q) may also be retained in megakaryocytes. We investigated patients who exhibited complete clearance of del(5q) as assessed by both standard karyotyping and FISH at one or more time points. In the MDS-004 trial, 6 of the 21 patients who had at least one follow-up biopsy after the first screening biopsy met this criterion and of these, 4 had high quality biopsies available matching the time point of CCyR (Table I) . We observed complete disappearance of the del(5q) abnormality at 12 weeks postrandomization for 3 patients and at 48 weeks in the remaining patient. Morphological evaluation demonstrated the persistence of hypolobated megakaryocytes in all 4 cases ( Table I , Fig 1) . In addition, all 4 cases exhibited signs of erythroid hyperplasia and dysplasia as well as granulocytic dysplasia with few maturing granulocytic forms. Matsuda et al, 2007) and, if present, 40% (Germing et al, 2000) . *< 30 evaluable megakaryocytes in biopsy material.
In order to evaluate the observations from the MDS-004 clinical trial in an independent cohort, we studied 35 consecutive del(5q) MDS patients seen at Karolinska University Hospital, of which 22 patients were treated with lenalidomide (Scharenberg et al, 2017) . None of the 13 untreated patients achieved CCyR. However, of the 22 lenalidomide-treated patients, 8 patients achieved complete cytogenetic remission by FISH, with corresponding biopsy material available in 5 of these. In analogy with the MDS-004 cohort, hypolobated megakaryocytes were clearly identified in all these biopsies (Table I) .
Hypolobated megakaryocytes carry the 5q-abnormality and can be identified in tissue sections at complete cytogenetic remission
In order to verify that the abnormal hypolobated morphology of megakaryocytes is a direct result of the 5q-aberarration, we first identified megakaryocytes in situ and determined their del(5q) status. As the frequency of megakaryocytes in normal bone marrow smears is very low (<0Á05%), it was not possible to use standard archived material. In preliminary experiments, additional flow sorting of megakaryocytes proved to be difficult and purity was always below 10%, necessitating additional confirmation. Moreover, as most megakaryocytes are lost during standard densitygradient separation of bone marrow cells using Ficoll/Lymphoprep, a different protocol was developed. Using Percoll-density centrifugation and subsequent enrichment by magnetic-activated cell sorting-using CD61-microbeads, we were able to retrieve megakaryocytes and to perform FISH for the del(5q) abnormality on these cells. Megakaryocytes were readily identified using subsequent immunofluorescence labelling for CD61. However, identification of proper FISH signals proved to be difficult and this seemed specific to CD61+ cells. Nevertheless, we succeeded in the isolation and identification of megakaryocytes from the bone marrow of del(5q) patients at diagnosis in 3 cases. While the percentage of megakaryocytes carrying the del(5q) abnormality was somewhat variable (range, 40-89%), we observed FISH signals consistent with these cells carrying the 5q abnormality in all three cases. Regardless of nuclear content, the number of FISH signals for the 5q probe was approximately half of the 5p probe in megakaryocytes harbouring the del(5q) abnormality. Figures 2 and 3A show representative examples of megakaryocytes (with DNA content of 2N, 4N, 8N, and 16N, respectively) from 2 del(5q) patients with megakaryocytes identified by CD61-immunoflourescent labelling and concomitant FISH for del(5q).
Given our lack of available fresh bone marrow samples during CCyR, we turned to an alternative approach. On biopsy material available from one patient in CCyR (determined by both cytogenetics and FISH), we performed FISH on bone marrow tissue sections counterstained with haematoxylin-eosin. Again, FISH signals were easily identified in mononuclear cells but proved to be far more difficult to evaluate in megakaryocytes. Twenty-three megakaryocytes had sufficient quality for FISH signal evaluation; 20 demonstrated normal morphology and 3 showed the characteristic hypolobated del(5q) morphology. All 20 normal megakaryocytes had equal numbers of 5p and 5q signals. In contrast, 2 of the 3 hypolobated megakaryocytes showed twice the number of 5p signals as 5q signals, indicative of the del(5q) aberration ( Fig 3B) and 1 had equal signal numbers of 5p and 5q. Twelve months after the first detection of CCyR, the patient discontinued treatment due to adverse events, and the del(5q) clone reappeared 12 months later as detected by FISH according to clinical routine. 
Megakaryo-Erythroid Progenitor cells show high clonal involvement at diagnosis
Mature megakaryocytes are the descendants of myeloid progenitor cells. Our previous studies demonstrated that lenalidomide reduced del(5q) progenitor cells, but failed to eradicate HSC carrying del(5q) (Tehranchi et al, 2010) . Given that mature megakaryocytes contained a large fraction of 5q-deleted cells, we analysed progenitor cell subsets sorted from seven patients in the Karolinska cohort. We observed that the frequency of the del(5q) abnormality in HSC, CMP, Note the number of FISH signals for 5q (green) is half that of the probe for 5p (red). The nucleus was counterstained with DAPI. (B) Megakarycyte identification in situ. Tissue sections of Patient from the Karolinska cohort at time of CCyR were stained with haematoxylin-eosin and the ratio of hypolobated to normal megakaryocytes was determined. Subsequently, FISH was performed and 5p and 5q signals were evaluated in normal and hypolobated megakaryocytes. Shown is one of three hypolobated megakaryocytes out of 23 megakaryocytes evaluated in total (red = 5p, green = 5q, blue = DAPI).
(A) (B)
Fig 2. Direct evidence of del(5q) in isolated megakaryocytes. Megakaryocytes from del(5q) patients were enriched by CD61-immunomagnetic isolation and subsequently stained with anti-CD61 (AMCA, blue) before FISH analysis (red = 5q; green = 5p). Megakaryocyte with DNA contents of 2n and 4n (A) or 8n (B). Note the number of FISH signals for 5q (red) is half that of the probe for 5p (green).
GMP and MEP varied during lenalidomide treatment, showing no apparent association with duration of treatment (data not shown), in line with previous studies Scharenberg et al, 2017) . Interestingly however, the percentage of MEP carrying the del(5q) abnormality was consistently high at diagnosis (between 94% and 100%, n = 5, Fig 4) .
Discussion
We have previously reported clonal involvement of the HSC compartment in clinical and cytogenetic complete remission due to lenalidomide, but it has hitherto been considered that bone marrow precursors and mature cells lose the abnormality, as assessed by conventional cytogenetic and FISH analysis (G€ ohring et al, 2011) . Here, we report, for the first time, that dysplastic megakaryocytes in del(5q) MDS prevail in lenalidomide-induced clinical and cytogenetic remission, thus constituting a persistent reservoir of del(5q) in addition to del(5q) HSC. Moreover, the entire megakaryocyte lineage from HSC to MEP to megakaryocytes appears resistant to treatment. We also provide evidence that the pathognomonic hypolobated megakaryocyte in del(5q) MDS is associated with the clonal aberration. Irrespective of nuclear content, we found evidence of del(5q) in megakaryocytes of 2N, 4N and 16N, suggesting that hypolobation is not directly correlated to nuclear content, as suggested by mouse models of del(5q) MDS (Barlow et al, 2010) . Due to their rarity and readily identifiable morphology, our finding of hypolobated and clonal megakaryocytes in patients with CCyR suggests that megakaryocytes might be an ideal bone marrow cell to focus on when evaluating patients for long-term remission and complete disappearance of del(5q). In this regard, it is interesting to note that one of our patients with complete haematological remission 2 years after discontinuation of lenalidomide (Scharenberg et al, 2017) , showed clonal involvement in 2 of 23 megakaryocytes. However, studies in a larger number of patients achieving long-term transfusion independence with or without CCyR are required to better understand the relationship. We suggest that megakaryocyte morphology could be surveyed in patients where discontinuation of lenalidomide is considered.
A subsequent question is whether the specific resistance of the megakaryocyte lineage plays a role in the high relapse rate of disease in patients successfully treated with lenalidomide, with or without continued treatment. Our data does not evaluate the functional role of del(5q) persistence in this context but offers a novel basis for hypotheses. Various niches in the bone marrow microenvironment regulate distinct cellular entities of HSC and haematopoietic progenitor cells (HSPC) as well as more mature cells. The cellular components of these niches are unique to the differentiation stage of the haematopoietic cells. An emerging model suggests that haematopoietic and mesenchymal niche cells are intertwined in a symbiotic relationship, each at particular stages in their respective differentiation (Morrison & Scadden, 2014) . Niche components supporting the maintenance, proliferation and differentiation of HSCs have been shown to consist of mesenchymal stem cells themselves and their mature descendants, e.g., osteoblastic and endothelial cells (Calvi et al, 2003; Zhang et al, 2003; M endez-Ferrer et al, 2010; Ding et al, 2012; Kfoury & Scadden, 2015) . In addition, some cells with ascribed niche function are derived from HSC themselves, e.g., the macrophage (Winkler et al, 2010) . Moreover, recent studies in mouse models demonstrated that megakaryocytes are part of the niche that HSC reside in (Bruns et al, 2014; Zhao et al, 2014) . These studies suggest that megakaryocytes potentially can play an important role in regulating the proliferation and quiescence of HSC. However, there is a paucity of data about potential similar regulation in the human system.
Our study demonstrates that characteristic hypolobated and clonal megakaryocytes persist even when the del(5q) abnormality cannot be detected by standard cytogenetics or FISH on mononuclear cells. Moreover, we observe that MEP demonstrate a similar degree of clonal involvement as HSC, at least at diagnosis (Fig 4) . Provided that megakaryocytes in the human system constitute a similarly integral part of the HSC niche, the question is whether del(5q) megakaryocytes might alter this niche in a way that contributes to the resistance of del(5q) HSC against lenalidomide. In this context, it is especially interesting to note the existence of HSC with primed differentiation towards the megakaryocytic lineage (Sanjuan-Pla et al, 2013; Yamamoto et al, 2013; Haas et al, 2015) . Notably, these megakaryocytic/platelet-biased HSC have been suggested to reside at the apex of the HSC hierarchy and the evidence for fast-track differentiation from HSC to MEP to megakaryocytes might explain the high-degree of resistance in the megakaryocytic lineage as a whole.
We believe that our study, in addition to aiding in the clinical evaluation of response, offers interesting hypotheses (5q) patients (n = 7) before lenalidomide treatment were isolated by flow cytometric cell sorting and analysed by FISH. CMP, common myeloid progenitors (n = 7); FISH: fluorescence in situ hybridization; GMP, granulocytic-myeloid progenitors (n = 5); HSC, haematopoietic stem cells (n = 7); MEP, megakaryo-erythroid progenitors (n = 5).
for further investigation of the resistance of del(5q) MDS to lenalidomide. It may be hypothesized that del(5q) HSC and megakaryocytes can favour each other's existence. Interestingly, lenalidomide is known to cause thrombocytopenia, and one can speculate whether or not this is related to its therapeutic effect. Moreover, we entertain the notion that specifically targeting megakaryocytes might result in additional therapeutic -perhaps even curative -potential for patients with del(5q) MDS.
